Molecular Cancer

Article	Citations
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	1926
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	1002
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	954
ERK mediates interferon gamma-induced melanoma cell death	881
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance	741
The puppet master in the breast cancer “microecological community”: spatial and metabolic regulation of macrophage heterogeneity	721
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers	621
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	583
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers	507
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	479
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	450
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	405
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	397
Immunotherapies in rare cancers	371
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	360
TGF-β signaling promotes cervical cancer metastasis via CDR1as	358
Mutation-specific dynamics of dedifferentiation trajectories and tumor–stromal interactions in thyroid cancer	324
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	307
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	303
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	302
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	295
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	280
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	280
Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer	268
Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance	266

circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	260
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	259
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	248
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	247
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	243
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	242
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	241
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	241
Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages	236
Biomarker-empowered precision navigation of CAR-T cell therapy	231
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia	230
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	225
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	223
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	221
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	219
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	213
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	212
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	212
Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response	206
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	202
LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target	202
Effects of RNA methylation on Tumor angiogenesis and cancer progression	201
Bidirectional role of neutrophils in tumor development	193
Emerging roles of tRNA-derived fragments in cancer	192
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	191
NK cells are never alone: crosstalk and communication in tumour microenvironments	191
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	190
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	189
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	185
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	183
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	182
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	179
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	179
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	178
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	174
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	174
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	173
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	173
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	172
Metabolic reprogramming and molecular crosstalk at the cancer–endothelial interface in ovarian carcinoma	170
Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids	168
Deconstructing cancer in 3D: models, mechanisms, and personalized solutions	164
Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	164
Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation	161
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	158
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis	158
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	158
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	157
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	157
Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation	154

lncRNAs: the unexpected link between protein synthesis and cancer adaptation	147
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	145
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	144
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	144
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	138
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	138
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	132
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	131
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	131
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	129
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	126
Context-dependent impact of type I interferon signaling in cancer	124
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	124
Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers	124
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	124
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	123
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	122
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	122
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	121
Molecular mechanisms of tumor resistance to radiotherapy	121
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	119
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	116
Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges	115
Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies	115
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	114
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	113
Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer	113
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	111
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	111
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	109
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	109
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy	108
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	107
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives	107
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors	106
Therapy-induced senescence is a transient drug resistance mechanism in breast cancer	106
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond	105
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	104
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer	104
Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues	104
Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma	104
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response	104
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer	103
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway	103
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy	99
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	96
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis	96
Targeting metastasis in paediatric bone sarcomas	96
Retraction Note: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer	95
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1	95
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges	95
A high proportion of germline variants in pediatric chronic myeloid leukemia	94
Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming	94
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma	94
Targeting MYC in T-Cell lymphoma via epigenetic modulation with a small-molecule inhibitor	93
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway	91
Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing	90
CircKIAA1617 promotes stemness via USP14/PGRMC1-mediated autophagy and lipid metabolism reprogramming in ER-positive breast cancer	89
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer	88
A non-complement role for C1R rewires integrin and death-receptor signaling to drive renal cancer metastasis	88
Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer	87
Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine	87
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination	86
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling	86
Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4–HDAC4–RUNX2–GAMT-mediated apoptosis	86
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective	84
Biological and pharmacological roles of m6A modifications in cancer drug resistance	84
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis	84
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better	84
Integrating single cell- and spatial- resolved transcriptomics unravels the inter-tumor heterogeneity and immunosuppressive landscape in HBV- and Clonorchis sinensis-associated hepatocellular carcinom	83
Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target	83
Beyond the mouse: 3R-guided alternative animal models transforming cancer research	82
EIF4A3/circPTGR1/miR-4725-5p positive- feedback loop promotes colorectal cancer progression via FAK/AKT signaling pathway	82
Inflammation in cancer: therapeutic opportunities from new insights	81
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells	80
Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	80
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation	80
Exosomal miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2	80
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	79
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025	79

Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance	78
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research	78
Correction: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression	78
CBFA2T2: a novel H3K27 reader regulating metabolism and tumor growth	78
Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis	77
Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma	77
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development	76
Shifting landscapes of gender equity in oncology journals: a decade of authorship trends	76
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer	76
[18F]FDG PET/CT multiomics identifies Hedgehog-driven HPV-negative head and neck squamous cell carcinoma	76
Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway	76
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies	75
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells	75
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma	75
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors	74
Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers	73
Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency	73
Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma	73
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy	72
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy	72
A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities	72
CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis	72
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	72
Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma	71
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions	71
Correction: Cell‑autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53‑driven senescence and confers an immune‑active tumor microenvironment	71
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis	71
Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials	71
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment	70
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy	70
Exploiting innate immunity for cancer immunotherapy	69
Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy	69
Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network	69
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	69
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	68
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	68
CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance	68
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	68
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	68
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	67
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates	66
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	65
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	64
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	64
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation	64
Expression of mTOR in normal and pathological conditions	63
c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT	63
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	63
STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy	63
Multifunctional chitosan–doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy	63
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	62
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	62
Extracellular vesicles in tumor immunity: mechanisms and novel insights	62
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	62
Lactate: elucidating its indispensable role in human health	62
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	62
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	61
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	61
Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion	61
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations	60
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	60
A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction	60
Commentary on “Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells”	60
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	60
Non-coding RNAs as master regulators of ferroptosis in cancer: mechanisms and clinical implications	60
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	60
Correction: Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer	59
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	59
Correction: ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH	59
Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma	59
​​The immune microenvironment of pathogen-associated cancers and current clinical therapeutics	58
The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy	58
Targeting HASPIN-mediated H3T3 phosphorylation disrupts an epigenetic-kinesin axis to suppress colorectal cancer mitotic progression	58
Correction: Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling	58
Traditional Chinese medicine in the treatment of breast Cancer	58
Metabolic reprogramming in cancer: signaling pathways and therapeutic targets	58
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs	57
Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting	57
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy	57
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy	57
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	57
CAR T cells: engineered immune cells to treat brain cancers and beyond	57
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring	56
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy	56
Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer	55
HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4–ERK1/2–U2AF2–TFRC axis	54
Spatial proteomics reveals four-stage molecular evolution in cancer immunotherapy-related gastritis	54
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer	54
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	54
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	54
Transfer RNA-derived small RNAs in tumor microenvironment	53
Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop	53
Retraction Note: N6-methyladenosine induced mir-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1	52
NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defects	52
Correction: CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug	52